Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Equillium Inc (NQ: EQ )

1.800 +0.080 (+4.65%)
Streaming Delayed Price Updated: 10:26 AM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 23,541
Open 1.740
Bid (Size) 1.740 (19)
Ask (Size) 1.800 (12)
Prev. Close 1.720
Today's Range 1.740 - 1.810
52wk Range 0.4500 - 3.250
Shares Outstanding 34,414,149
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
From Equillium, Inc.
Via Business Wire
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Equillium, Inc.
Via Business Wire

Performance

YTD
+145.13%
+145.13%
1 Month
-6.25%
-6.25%
3 Month
+125.00%
+125.00%
6 Month
+263.64%
+263.64%
1 Year
+233.15%
+233.15%

More News

Read More
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
From Equillium, Inc.
Via Business Wire
Equillium: Q4 Earnings Insights
Via Benzinga
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
From Equillium, Inc.
Via Business Wire
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
From Equillium, Inc.
Via Business Wire
5 Stocks That More Than Doubled In February
Via Talk Markets
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Cognizant Technology Solutions To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease
From Equillium, Inc.
Via Business Wire
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology
From Equillium, Inc.
Via Business Wire
Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
From Equillium, Inc.
Via Business Wire
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
From Equillium, Inc.
Via Business Wire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Via ACCESSWIRE
Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology
From Equillium
Via Business Wire
Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium
From Equillium Inc.
Via Business Wire
Equillium to Host Analyst & Investor Day
From Equillium, Inc.
Via Business Wire
Equillium to Present at the JonesTrading 2023 Healthcare Summit
From Equillium, Inc.
Via Business Wire
Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences
From Equillium, Inc.
Via Business Wire
Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference
From Equillium, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.